Differentiating Stem Cells
Reliable and scalable differentiation of stem cells in serum-free conditions is predicted to be one of the most significant barriers to their commercialization for drug discovery or clinical applications, according to Jey M. Jeyakumar, Ph.D., principal scientist at Plasticell Limited. “While advances in regenerative medicine are reported daily, clinical-grade stem cell differentiation media is still considered to be a major challenge in the field.
“Differentiating stem cells requires their culture in a series of different cell culture media over time, each medium containing many different components,” says Dr. Jeyakumar. “This creates a combinatorial problem when trying to discover differentiation protocols using conventional methods. Searching for such protocols may take teams of scientists many months if not years and consumes a lot of resources. Even then, the resultant protocols may not optimal; that is, they may only be weakly effective.”
Plasticell’s high-throughput platform for differentiating stem cells, called combinatorial cell culture (CombiCult®), tackles this problem using a bead-based screening method that allows sampling of up to 100,000 putative protocols in parallel in the time it takes for the stem cell to differentiate, that is, weeks.
According to Dr. Jeyakumar, “CombiCult allows us to perform up to 100,000 trial-and-error equivalent experiments in parallel. This allows for the very rapid, low-risk, and cheap discovery of stem cell differentiation protocols. That is, it serves as a search engine for stem cell differentiation protocols.”
The technology has been used successfully in the differentiation of embryonic stem cells, tissue stem cells, and induced pluripotent stem cells toward defined lineages, validating the technology and showing proof of its many applications.
“We obtained a ranked list of protocols that are highly specific for osteocytes and chondrocytes using bone-marrow-derived mesenchymal stem cells (MSCs). In addition, for the first time in the industry, these protocols were serum-free, devoid of animal-derived components, and scalable. In the case of the osteocyte media, they turned out to be highly effective at differentiating MSCs into bone cells that secrete the mineral components for bone.”
Dr. Jeyakumar projects that adoption of these techniques will rapidly accelerate efforts to industrialize stem cell differentiation by pharma and the field of regenerative medicine.